Sophie Lamle, DPhil, is the new Executive Vice President (EVP) of Development at LEO Pharma, effective Dec. 1, 2025.
Prior to her start, Mark Levick will conclude his tenure as interim EVP but will continue serving as a member of the Board of Directors and Chair of the Innovation Committee.
Lamle joins LEO Pharma from Teva Pharmaceuticals, where she led the global R&D innovative medicines team, overseeing assets across Immunology and Neuroscience, from discovery through commercialization. Lamle has more than 20 years of experience in the pharmaceutical industry.
“I’m very much looking forward to becoming part of the LEO Pharma team, bringing purposeful innovation in medical dermatology. I’m passionate about making a fundamental difference for all those suffering from skin disease. The Search & Development model resonates strongly with me, as I am driven by forging strategic partnerships that accelerate asset progression and demonstrate value through differentiated clinical programs. I look forward to contributing to the next wave of growth at LEO Pharma,” says Lamle in a news release.
She is originally from the United Kingdom and has a D.Phil. in Chemistry from the University of Oxford. Prior to her role at Teva, she held roles in Vectura, Novartis Pharmaceuticals, and IQVIA.
“Sophie is a very strong international profile and passionate about making a fundamental difference through innovation. With her experience and know-how in partnerships and co-creation, as well as her strong leadership skills, she is the ideal candidate to lead Development in the next chapter of our journey,” says LEO Pharma CEO Christophe Bourdon.
